![]() ![]() Upon completion of the acquisition, GSK acquired all outstanding shares of Sierra Oncology for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.6 billion at current exchange rates). Sierra Oncology submitted a New Drug Application to the US Food and Drug Administration in June, and GSK anticipates a regulatory submission in Europe in the second half of 2022. The trial met all its primary and key secondary endpoints, demonstrating that momelotinib achieved a statistically significant and clinically meaningful benefit on symptoms, splenic response, and anaemia. In June 2022, Sierra Oncology presented the complete data from the MOMENTUM phase III trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. We now have a late-stage differentiated molecule in momelotinib, which could potentially address a significant unmet need in myelofibrosis patients with anaemia. Luke Miels, Chief Commercial Officer, GSK, said: “This acquisition expands our innovative oncology portfolio, demonstrating our commitment to improving patient outcomes and creating value for shareholders. If approved, momelotinib will contribute to GSK’s growing specialty medicines business, with a US launch anticipated in 2023. In addition, momelotinib complements GSK’s Blenrep (belantamab mafodotin) the acquisition builds on the company’s expertise in haematology and aligns with GSK’s strategy of building a strong portfolio of specialty medicines and vaccines. The acquisition was approved by Sierra Oncology's shareholders on 29 June 2022.Īs previously announced, the acquisition of Sierra Oncology includes momelotinib, a late-stage potential new medicine with a unique dual mechanism of action that may address the critical unmet medical needs of myelofibrosis patients with anaemia. (Sierra Oncology), a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer. GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Sierra Oncology, Inc. I’ll update this article as we get closer to their next sales event to let you know the best deals taking place.For media and investors only Issued: 1 July 2022, London UK It’s the perfect way to stay in loop on exclusives, new offers, future sales, and a ton more.Īs far as major sales events go, one of their biggest sales of the year takes place during the Black Friday and Cyber Monday weekend, where you can get up to 70% off site-wide. I suggest to subscribe to their emails (which is free) and they’ll provide you a free shipping code to use and, at times, an extra 10% coupon code you can use for your online purchase. But since they are already such a heavily discounted brand, it’s not often they have coupons and the like – although, yes, Sierra does accept codes on their site when you’re checking out.Īny coupons they’re going to offer will come directly from them. On any given day you can save up to 70% off some of their best sellers. I researched Sierra’s overall sales and major sales events throughout the year, along with their promo code policy. So whether you’re looking for something for yourself or need something for your kids (even gifts), they really have a great selection at even better prices. Overall there more than 100 different top brands to sort through direct from Sierra. Some of their biggest and most sought-after brands they carry include some of my personal faves like:Īnd that’s just naming a few. And their brand selection is really key as well. On average you can save anywhere from an extra 40% – 50% off, which is pretty amazing. Just about everything they carry in-store (and on their website) is heavily discounted from the original prices. I’m talking about some killer clothing, accessories, and equipment for men, women, kids – and even some fun stuff for your pets too! Some of their most popular offerings include things like: Sierra has been around since 1998 and carries just about everything you need to live your best outdoor life ever. ![]()
0 Comments
Leave a Reply. |